Opsona Therapeutics Limited, a Dublin-based immune drug development company, has announced that investor Omnes Capital has added 3 million euro to a Series C financing round that now totals 36 million euro.

Opsona plans to use the financing to supplement funding a three-part multi-centered, double-blinded and placebo-controlled clinical study to evaluate the safety, tolerability and efficacy of its lead product OPN-305 in renal transplant patients at high risk of Delayed Graft Function (DGF). Investors in this Series C round of financing include Novartis Venture Fund, Fountain Healthcare Partners, Roche Venture Fund, Seroba-Kernel Life Sciences, BB Biotech Ventures, Sunstone Capital, Baxter Ventures, Amgen Ventures and EMBL Ventures.

Opsona is a immunology drug development company, focused on therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 by three immunologists at Trinity College in Dublin.